Evidence map›Paper›PMID 41123589›Full record

ArticleeLife2025

Chromatin activity of IκBα mediates the exit from naïve pluripotency.

Luis G Palma, Daniel Alvarez-Villanueva, Maria Maqueda, Mercedes Barrero, Arnau Iglesias, Joan Bertran, Damiana Alvarez, Carlos A Garcia-Prieto, Cecilia Ballare, Virginia Rodriguez-Cortez and 10 more

Abstract read
In one paragraph

Article in eLife, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Luis G Palma *Program in Cancer Research. Hospital del Mar Research Institute, Barcelona, Spain.
Daniel Alvarez-Villanueva *Program in Cancer Research. Hospital del Mar Research Institute, Barcelona, Spain.
Maria MaquedaProgram in Cancer Research. Hospital del Mar Research Institute, Barcelona, Spain.
Mercedes BarreroCentre for Genomic Regulationlation(CRG), The Barcelona Institute of Science and Technology, Barcelona, Spain.
Arnau IglesiasProgram in Cancer Research. Hospital del Mar Research Institute, Barcelona, Spain.
Joan BertranUniversitat de Vic - Universitat Central de Catalunya, Vic, Spain.
Damiana AlvarezJosep Carreras Leukemia Research Institute, Barcelona, Spain.
Carlos A Garcia-PrietoJosep Carreras Leukemia Research Institute, Barcelona, Spain.
Cecilia BallareCentre for Genomic Regulationlation(CRG), The Barcelona Institute of Science and Technology, Barcelona, Spain.
Virginia Rodriguez-CortezJosep Carreras Leukemia Research Institute, Barcelona, Spain.
Clara BuenoJosep Carreras Leukemia Research Institute, Barcelona, Spain.
August VidalInstitut Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobrega, Barcelona, Spain.
Alberto VillanuevaCatalan Institute of Oncology (ICO/IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.
Pablo MenendezJosep Carreras Leukemia Research Institute, Barcelona, Spain.
Gregoire StikJosep Carreras Leukemia Research Institute, Barcelona, Spain.
Luciano Di CroceCentre for Genomic Regulationlation(CRG), The Barcelona Institute of Science and Technology, Barcelona, Spain.
Bernhard PayerCentre for Genomic Regulationlation(CRG), The Barcelona Institute of Science and Technology, Barcelona, Spain.
Manel EstellerJosep Carreras Leukemia Research Institute, Barcelona, Spain.
Lluis EspinosaProgram in Cancer Research. Hospital del Mar Research Institute, Barcelona, Spain.
Anna BigasProgram in Cancer Research. Hospital del Mar Research Institute, Barcelona, Spain.ORCID https://orcid.org/0000-0003-4801-6899

Funding

Agència de Gestió d'Ajuts Universitaris i de Recerca 2019 FI- B 00151Agència de Gestió d'Ajuts Universitaris i de Recerca 2020 FI_B1 00130Agència de Gestió d'Ajuts Universitaris i de Recerca 2021 SGR 01222Departament de Salut, Generalitat de Catalunya SLT002/16/00299Generalitat de Catalunya 2021SGR 39Instituto de Salud Carlos III CA22/00011Instituto de Salud Carlos III FI20/00130Ministerio de Ciencia e Innovación PDC2021-120817-I00Ministerio de Ciencia e Innovación PID2019-104695RB-I00Ministerio de Ciencia e Innovación PID2019-108322GB-100Ministerio de Ciencia e Innovación PID2021-123383NB-I00Ministerio de Ciencia e Innovación PID2022-137945OB-I00Ministerio de Ciencia e Innovación PID2022-142679NB-I00Ministerio de Ciencia e Innovación PLEC2021-007518
6 · The paper itself

Abstract

Maintenance of pluripotency is a multifactorial process in which NF-κB is a negative regulator. Our previous work identified a chromatin role for IκBα, the master regulator of NF-κB signaling, that is critical for the proper regulation of various tissue stem cells. Here, we found that IκBα accumulates specifically in the chromatin fraction of mouse pluripotent stem cells. IκBα depletion does not affect NF-kB-dependent transcription, but causes a profound epigenetic rewiring in pluripotent stem cells, including alterations in H3K27me3, a histone mark catalyzed by Polycomb repression complex 2. Chromatin changes induced by IκBα depletion affect a subset of pluripotency genes and are associated with altered gene transcription. At the cellular level, IκBα-deficient embryonic stem cells are arrested in a naive pluripotency state when cultured in serum/LIF conditions and fail to exit pluripotency under differentiation conditions. By constructing separation-of-function mutants, we show that the effects of IκBα in regulating stem cell pluripotency are NF-κB-independent, but mainly rely on its chromatin-related function. Taken together, our results reveal a novel mechanism by which IκBα participates in the regulation of the pluripotent state of mouse embryonic stem cells and shed light on the interplay between inflammatory signals and the regulation of pluripotency.

Indexed as

ChromatinMouse Embryonic Stem CellsNF-KappaB Inhibitor alphaPluripotent Stem CellsAnimalsCell DifferentiationEpigenesis, GeneticMiceNFI Transcription FactorsNF-kappa BChromatinNfia protein, mouseNFI Transcription FactorsNF-kappa BNF-KappaB Inhibitor alphaNfkbia protein, mouseembryonic stem cellsikappabalphamouseNFKBNFKBIApluripotency exitPRC2regenerative medicinestem cells

Identifiers

PMID41123589
PMCPMC12543326

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.